XSHG
600771
Market cap1.02bUSD
Oct 09, Last price
14.38CNY
1D
2.64%
1Q
1.05%
Jan 2017
-39.80%
Name
GuangYuYuan Chinese Herbal Medicn Co Ltd
Chart & performance
P/E
111.65
P/S
5.14
EPS
0.13
Div yield, %
—
Shrs. gr., 5y
-0.19%
Rev. gr., 5y
4.30%
Revenues
1.37b
+12.11%
Net income
63m
-15.32%
CFO
198m
+76.07%
Dividend
Jul 30, 20030.0648 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
GuangYuYuan Chinese Herbal Medicine Co., Ltd. specializes in the production and sale of traditional Chinese pharmaceutical goods. Their comprehensive range includes both classic and high-quality Chinese medicines, in addition to health-boosting wines. These remedies are available in diverse formats, such as pills, powders, tablets, hard capsules, granules, oral liquids, decoctions, and various wine preparations. The enterprise, which previously operated as Topsun Science And Technology Co Ltd., adopted its current name, GuangYuYuan Chinese Herbal Medicine Co., Ltd., in July 2013. Its primary operations are located in Xi'an, China.
Key people
Peng Liang
Vice President · since 2020
Zhong Li
Deputy General Manager · since 2020
Min Qiu
Secretary of the Board · since 2020
Shuhong Fu
Chief Financial Officer, Director · since 2010
Zhilin Xu
Director
Chengmin Pu
Independent Director · since 2010
Lei Shi
Independent Director
Bin Wu
Independent Director · since 2020
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||